Spinal muscular atrophy

Eugenio Mercuri, Charlotte J. Sumner, Francesco Muntoni, Basil T. Darras, Richard S. Finkel

Research output: Contribution to journalArticlepeer-review


Spinal muscular atrophy (SMA) is a neurodegenerative disorder caused by mutations in SMN1 (encoding survival motor neuron protein (SMN)). Reduced expression of SMN leads to loss of α-motor neurons, severe muscle weakness and often early death. Standard-of-care recommendations for multidisciplinary supportive care of SMA were established in the past few decades. However, improved understanding of the pathogenetic mechanisms of SMA has led to the development of different therapeutic approaches. Three treatments that increase SMN expression by distinct molecular mechanisms, administration routes and tissue biodistributions have received regulatory approval with others in clinical development. The advent of the new therapies is redefining standards of care as in many countries most patients are treated with one of the new therapies, leading to the identification of emerging new phenotypes of SMA and a renewed characterization of demographics owing to improved patient survival.

Original languageEnglish (US)
Article number52
JournalNature Reviews Disease Primers
Issue number1
StatePublished - Dec 2022

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Spinal muscular atrophy'. Together they form a unique fingerprint.

Cite this